Interakcje soku grejpfrutowego ze statynami

• Autorzy: Grzybek A

Warianty tytułu

LA

Grapefruit juice-statins interaction

• Języki publikacji: PL

Słowa kluczowe

PL

zdrowie czlowieka; interakcje; styl zycia; zywnosc; grejpfruty; statyny; leki; sok grejpfrutowy; zywienie czlowieka

• Wydawca: -
• Czasopismo: Żywienie Człowieka i Metabolizm
• Rocznik: 2005
• Tom: 32
• Numer: 3
• Opis fizyczny: s.254-261,bibliogr.

Twórcy

autor

Grzybek A

• Instytut Zywnosci i Zywienia, Warszawa

Bibliografia

• 1. Bailey D G., Spence J.D., Munoz G, Arnold J.M.: Interaction of citrus juices with felodipine and nifedipine. Lancet 1991, 337, 8736, 268-269.
• 2. Bailey D.G., Malcolm J., Spence D.: Grapefruit juice-drug interactions. Br. J. Clin. Pharmacol., 1998 46 101-110.
• 3. Bailey D.G., Dresser G., Kreeft J.H., et al.: Grapefruit-felodipine interaction: effect of unprocessed fruit and probable active ingredients. Clin. Pharmacol. Ther., 2000, 68, 468-77.
• 4. Bazzano L.A., He J., Ogden L.G., et al.: Dietary fiber intake and reduced risk of coronary heart disease in US men and women: the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Arch. Intern. Med., 2003, 163, 1897-1904.
• 5. Biochemia Harpera. Pod red. Murray R. Metabolizm ksenobiotyków. Warszawa, PZWL, 2002. 6.Edwards D.J., Bellevue EH., Woster P.: Identification of 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor in grapefruit juice. Drug Metab. Dispos., 1996, 24, 1287-1290.
• 7. Edwards D.J., Bernier SM.: Naringin and naringenin are not the primary CYP3Ain- hibitors in grapefruit juice. Life Sei., 1996, 59, 1025-1030.
• 8. Fukuda K., Ohta T., Ohashi N., et al.: Specific CYP3A4 inhibitors in grapefruit juice: furocumarin dimmers as components of drug interactions. Pharmacogenetics 1997, 7, 391-396.
• 9. Fukuda K., Ohta T., Yamazone Y.: Grapefruit component interacting with rat and human P450 CYP3A: possible involvement of non-flavonoid components in drug interaction. Biol. Pharm. Bull., 1997, 20, 560-564.
• 10. Fukuda K., Gou L., Ohashi N., et al.: Amounts and variation in grapefruit juice of the main components causing drug-drug interaction. J. Chromatogr. Biomed. Sei. Appl., 2000, 12, 195-203. 11. Guo L-Q., Fukuda K., Ohta T.: Role of furanocoumarin derivates on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab. Dispos., 2000, 28, 766-771.
• 12. Guo L-Q., Taniguchi M., Xiao Y-Q., et al.: Inhibitory effect of natural furanocoumarins on human microsomal citochrome P450 3A activity. Jpn. J. Pharmacol., 2000, 82, 122-129.
• 13. Guo L-Q., Yamazoe Y.: Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacol. Sin., 2004, 25, 129-136.
• 14. Jacobsen W., Kirchner G., Hallensleben K., et al.: Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Lovastatin and comparison with Pravastatin. J. Pharmacol. Exp. Ther., 1999, 291, 1631-1639.
• 15. Kane G., Lipsky J.: Drug-grapefruit juice interactions. Mayo Clin. Proc., 2000, 75, 933-942.
• 16. Kantola T., Kivisto K.T., Neuvonen PJ.: Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther., 1998, 63, 397-402.
• 17. Knekt P, Jarvinen R., Reunanen A.: Flavonoid intake and coronary mortality in Finland: a cohort study" Br. Med. J., 1996, 312, 478-481.
• 18. Lilja J.J., Kivisto K.T., Neuvonen P.J.: Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid and HMG-CoA reductase inhibitors. Clin. Pharmacol. Ther., 1998, 64, 477-483.
• 19. Lilja J.J., Kivisto K.T., Neuvonen PJ.: Grapefruit juice increases serum concentrations of atorvastatin has no effect on pravastatin. Clin. Pharmacol. Ther., 1999, 66, 118-127.
• 20. Lilja J.J., Kivisto K.T., Neuvonen PJ.: Duration of effect of grapefruit juice on the pharmacokinetic of the CYP3A4 substrate simvastatin. Clin. Pharmacol. Ther., 2000, 68, 384-390.
• 21. Lilja J.J., Kivisto K.T., Neuvonen P.J.: Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br. J. Clin. Pharmacol., 2004, 58, 56-60.
• 22. Lown K, Bailley D., Fontana R., et al.: Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest., 1997, 99, 2545-2553. 23. Lundahl J., Regardh C., Edgar B., et al.: Effects of grapefruit juice ingestion - pharmacokinetics and haemo- dynamics of intravenously and orally administred felopidine in healthy men. Eur. J. Clin. Pharmacol., 1997, 52, 139-145.
• 24. Ness A., Powles J.: Fruit and vegetables and cardiovascular disease: a review. Int. J. Epidemiol., 1997, 26, 1-13.
• 25. Panagiotakos D., Pitsavos Ch., Kokkinos P., et al.: Consumption of fruits and vegetables in relation to the risk of developing acute coronary syndromes; the CARDIO 2000 case-control study. Nutrition Journal 2003, 2, 2-7.
• 26. Ping Chuen Ho, Saville D.: Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J. Pharm. Pharmaceut. Sei., 2001, 4, 217-227.
• 27. Prueksaritanont T., Gorham L., Ma B., et al.: In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of drug on hepatic P450s. Drug Metab. Dispos., 1997, 25, 1191-1199.
• 28. Rogers J., Zhao J., Liu L., et al.: Grapefruit juice has minimal effects on plasma concentration of lovasta- tin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin. Pharmacol. Ther., 1999, 66, 358-366.
• 29. Saita T., Fujito H., Mori M.: Screening of furanocoumarin derivates in citrus fruits by enzymelinked immunosorbent assay. Biol. Pharm. Bull., 2004, 27, 974-977.
• 30. Schmiedlin-Ren P., Edwards D., Fitzsimmons M., et al.: Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Drug Metab. Dispos., 1997, 25, 1228-1233.
• 31. Thompson P., Clarkson P, Karas R.: Statin-associated myopathy. J. Amer. Med. Assoc., 2003, 289, 1681-1690.